Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Cardiovascular

Sun Backs India-First Stroke Drug From Pharmazz

Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial.  The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.

Commercial India

Alnylam/Roche’s Zilebesiran Affirms Efficacy, But Commercially Relevant Data Await

The KARDIA-1 monotherapy study was successful, but KARDIA-2 will give a better sense of the market opportunity.

Clinical Trials Cardiovascular

Corteria Rides Wave Of Renewed Interest In Heart Failure

A French biotech led by Philip Janiak, former head of cardiovascular research at Sanofi, is looking to bring therapies to heart failure subpopulations with high unmet needs.

Financing Cardiovascular

Johnson & Johnson Gets Its Aprocitentan Money Back

The US company has returned rights to the hypertension product to Idorsia, which was already in the grip of a cash crunch and will now face greater difficulties getting the drug to market. 

Deals Blood & Coagulation Disorders

Now Europe’s Most Valuable Company, Can Novo Nordisk Live Up To Investor Expectations?

Novo Nordisk has just become Europe’s most valuable company based on Wegovy’s huge success so far and future potential - but just how big could the obesity market get?

Metabolic Disorders Cardiovascular

Bayer Expands Kerendia Program In Competitive Heart Failure Space

The drug maker added three investigator-initiated studies that will enroll more than 9,000 patients to the existing 6,000-patient MOONRAKER program. It has forecast peak sales of

Clinical Trials Business Strategies

LIB Therapeutics Has An Unorthodox Funding Method And Big Plans

Armed with highly satisfactory Phase III cholesterol-lowering data, the private group is heading to market alone – though it is open to offers. 

Clinical Trials Commercial

LIB Therapeutics Looks Competitive With Big Pharma in Hypercholesterolemia

Phase III results with lerodalcibep are in the same ballpark as heavy-hitting established PCSK9 inhibiting drugs.

Clinical Trials Companies

Novartis Lauds Long-Term Benefits Of Leqvio At ESC

Putting aside access issues for Leqvio, Novartis has presented data showing that the small interfering RNA directed PCSK9 twice-a-year injection provides consistent low-density lipoprotein cholesterol reduction over six years and more.

Cardiovascular Clinical Trials

BridgeBio ATTR-CM Data Ignite Discussion Around Financing, Partnerships

The company presented detailed data for acoramidis at the ESC meeting over the weekend, though some data points like time to first CV hospitalization have not yet reported out.

Clinical Trials Business Strategies

Merck’s Anti-PCSK9 Pill Sets Up Convenience Battle Against Infrequently Dosed Injectables

The drug maker announced the start of a Phase III program for its oral PCSK9 inhibitor MK-0616, including a 14,550-patient outcomes trial set to start later in the year.

Clinical Trials Business Strategies

Novo Nordisk STEPs Into Heart Failure

The company’s metabolic juggernaut looks like a winner in obesity plus HFpEF, but making comparisons with approved products is tricky – and meeting demand is trickier still.

Clinical Trials Cardiovascular
See All